‡a
Author's Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
‡a
Author's Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells
‡a
Author's Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region
‡a
conformationalcontrolinhibitionofthebcrabl1tyrosinekinaseincludingthegatekeepert315imutantbytheswitchcontrolinhibitor700
‡A
Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
‡9
1
‡a
switchcontrolpocketinhibitorsofp38mapkinasedurabletype2inhibitorsthatdonotrequirebindingintothecanonicalatphingeregion
‡A
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region
‡9
1
‡a
discoveryof133dimethylbutyl32fluoro4methyl57methyl2methylaminopyridopyrimidin6ylphenylurealy3009120asapanrafinhibitorwithminimalparadoxicalactivationandactivityagainstbraforrasmutanttumorcells
‡A
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells
‡9
1
‡a
neuraminidasepotencyassayforquantitativeassessmentofneuraminidaseininfluenzavaccines
‡A
A neuraminidase potency assay for quantitative assessment of neuraminidase in influenza vaccines
‡9
1
